LEXINGTON, Mass. & SYDNEY--(GI Dynamics, Inc. (ASX: GID), a company pioneering the development of effective non-surgical approaches for treating type 2 diabetes and obesity, announced today that the company has been invited to present at the UBS Global Life Sciences Conference on Wednesday, September 21, 2011, at 8 a.m. EDT (10 p.m. Australian EST) to be held at the Grand Hyatt New York Hotel in New York City.)--
Stuart A. Randle, president and chief executive officer of GI Dynamics, will present an overview of the company and the EndoBarrier, a novel approach for the treatment of type 2 diabetes and obesity. The EndoBarrier has received CE mark approval in Europe for implant periods of up to 12 months of treatment for type 2 diabetes and obesity, and recently received TGA approval in Australia.
A live webcast of the GI Dynamics presentation can be accessed by visiting the investors section of the company's website at investor.gidynamics.com. A replay of the webcast will be archived on the GI Dynamics website (www.gidynamics.com) for two weeks following the presentation date.
About GI Dynamics
GI Dynamics, Inc. (ASX: GID) is pioneering the development and commercialization of effective, non-surgical treatments targeting the large and growing global patient populations with type 2 diabetes and obesity. The company’s flagship product, the EndoBarrier®, is a novel, non-surgical device proven to lower blood glucose levels and promote weight loss in diabetic and obese patients during the implant period. GI Dynamics currently markets the EndoBarrier in select regions in Europe and South America and is planning significant near-term commercial expansion into Australia and additional European countries. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com.
This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our EndoBarrier® including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. GI Dynamics does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. GI Dynamics may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, described in “Risk Factors” in our Prospectus lodged with the Australian Securities & Investments Commission on 3 August 2011.